<DOC>
	<DOCNO>NCT00136903</DOCNO>
	<brief_summary>To establish safety efficacy two dose level Ex-vivo Cultured Adult HumanMesenchymal Stem Cells ( Prochymal ) subject experience acute GVHD , Grades II-IV , post HSC transplant .</brief_summary>
	<brief_title>Safety Efficacy Study Adult Human Mesenchymal Stem Cells Treat Acute GVHD .</brief_title>
	<detailed_description>Protocol 260 - Subjects randomize equal probability treatment arm ( 2 million cells/kg Prochymal 8 million cells/kg Prochymal ) use stratified block design . The stratification factor acute GVHD grade . For purpose stratification , GVHD grade II III-IV . Treatment investigational agent administer study Days 1 4 . Patients follow safety efficacy Day 28 initiation treatment investigational agent , withdrawal death , whichever occur first . Protocol 261 - Subjects evaluate safety 2 year Day 1 precede Prochymal® Protocol No . 260 withdrawal death .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Protocol 260 Subjects must 18 70 year age inclusive If female childbearing age , subject must nonpregnant , breast feeding , use adequate contraception . Males must use adequate contraception . Subject must newly diagnose , Grade IIIV acute GVHD require therapy . Biopsy confirmation GVHD mandatory , recommend feasible . Enrollment delay await biopsy result . Subject must receive either full reduce intensity myeloablative regimen follow allogeneic hematopoietic stem cell transplant use bone marrow , peripheral blood stem cell , cord blood , include DLI Subjects must minimal renal hepatic function define : * Calculated creatinine clearance ( CLcr ) &gt; 30 mL/min use CockroftGault equation Subject must available specified assessment study site study Day 28 . Subjects must provide write informed consent authorization use disclosure protect health information ( PHI ) . Protocol 260 Subject receive previous treatment Grade IIIV acute GVHD ( except note criterion 2 ) . Subject treat GVHD methylprednisolone , &gt; 2mg/kg/day , 72 hour prior receive Prochymal™ Subject uncontrolled alcohol substance abuse within 6 month randomization . Subject receive investigational agent ( approved FDA market use indication ) within 30 day randomization . Subjects may receive investigational agent 28day study period Subject underlie current medical psychiatric condition , opinion Investigator , would interfere evaluation subject ( e.g. , uncontrolled infection , right heart failure , pulmonary hypertension , etc . ) Subject unstable arrhythmia Subject unwilling sign consent form longterm followup study , protocol No . 261 Subject know allergy bovine porcine product . Subject receive transplant solid tumor disease . Protocol 261 Subject must receive treatment Investigational Agent precede Prochymal® study . Subject must complete participation precede Prochymal® study . If female childbearing age , subject must nonpregnant , breastfeed , use adequate contraception . Male subject must use adequate contraception . Subject must provide write informed consent write authorization disclosure use PHI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Graft v Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>Bone marrow transplant</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Adult stem cell</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>